<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Sun E</submitter><funding>National Institutes of Health National Cancer Institute</funding><funding>National Center for Research Resources</funding><funding>U.S. Department of Health and Human Services</funding><funding>National Institute of Diabetes and Digestive and Kidney Diseases</funding><funding>Georgia Clinical and Translational Science Alliance</funding><funding>Vanderbilt Institute for Clinical and Translational Research</funding><funding>National Institutes of Health</funding><funding>Vanderbilt Cancer Center</funding><pagination>1185-1194</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12799435</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>122(5)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Carnobacterium maltaromaticum and Faecalibacterium prausnitzii induce de novo gut synthesis of vitamin D to inhibit colorectal carcinogenesis in mice. Magnesium (Mg) treatment increases circulating vitamin D, and Mg homeostasis is dependent on TRPM7 genotype.&lt;h4>Objectives&lt;/h4>We hypothesize that Mg treatment increases gut C. maltaromaticum and F. prausnitzii, and the effect differs by TRPM7 polymorphism.&lt;h4>Methods&lt;/h4>The Personalized Prevention of Colorectal Cancer Trial is a double-blind, precision-based randomized controlled trial with 240 participants randomly assigned to both treatment and TRPM7 genotype. Stool, rectal swabs, and rectal mucosa were collected.&lt;h4>Results&lt;/h4>Of 239 participants who completed the trial, 226 with valid microbiome data were analyzed (</pubmed_abstract><journal>The American journal of clinical nutrition</journal><pubmed_title>Magnesium treatment increases gut microbiome synthesizing vitamin D and inhibiting colorectal cancer: results from a double-blind precision-based randomized placebo-controlled trial.</pubmed_title><pmcid>PMC12799435</pmcid><funding_grant_id>UL1 RR024975</funding_grant_id><funding_grant_id>UL1TR000445</funding_grant_id><funding_grant_id>P30CA68485</funding_grant_id><funding_grant_id>VR12960</funding_grant_id><pubmed_authors>Murff HJ</pubmed_authors><pubmed_authors>Azcarate-Peril MA</pubmed_authors><pubmed_authors>Yu C</pubmed_authors><pubmed_authors>Dai Q</pubmed_authors><pubmed_authors>Sun S</pubmed_authors><pubmed_authors>Fan L</pubmed_authors><pubmed_authors>Shrubsole MJ</pubmed_authors><pubmed_authors>Sun E</pubmed_authors><pubmed_authors>Zhu X</pubmed_authors><pubmed_authors>Ness RM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Magnesium treatment increases gut microbiome synthesizing vitamin D and inhibiting colorectal cancer: results from a double-blind precision-based randomized placebo-controlled trial.</name><description>&lt;h4>Background&lt;/h4>Carnobacterium maltaromaticum and Faecalibacterium prausnitzii induce de novo gut synthesis of vitamin D to inhibit colorectal carcinogenesis in mice. Magnesium (Mg) treatment increases circulating vitamin D, and Mg homeostasis is dependent on TRPM7 genotype.&lt;h4>Objectives&lt;/h4>We hypothesize that Mg treatment increases gut C. maltaromaticum and F. prausnitzii, and the effect differs by TRPM7 polymorphism.&lt;h4>Methods&lt;/h4>The Personalized Prevention of Colorectal Cancer Trial is a double-blind, precision-based randomized controlled trial with 240 participants randomly assigned to both treatment and TRPM7 genotype. Stool, rectal swabs, and rectal mucosa were collected.&lt;h4>Results&lt;/h4>Of 239 participants who completed the trial, 226 with valid microbiome data were analyzed (</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-06T22:25:26.365Z</modification><creation>2026-06-06T03:07:42.174Z</creation></dates><accession>S-EPMC12799435</accession><cross_references><pubmed>40946805</pubmed><doi>10.1016/j.ajcnut.2025.09.011</doi></cross_references></HashMap>